Investment firm offers to buy Vancouver, B.C.-based biotech Zymeworks for $733M in cash Global investment firm All Blue Capital has offered to buy Zymeworks, a public biotech company based in Vancouver, B.C., with… Read More
Zymeworks aims to raise $100M in public offering amid leadership shakeup Zymeworks is looking to raise $100 million in a public offering, barely a week since new CEO Kenneth Galbraith took… Read More
New CEO at Zymeworks shifts leadership, plans to lay off 25% of staff Kenneth Galbraith is shaking up Zymeworks within a week of becoming CEO of the Seattle and Vancouver, B.C.-based biotech company.… Read More
Tech Moves: Adaptive CFO to resign; Meta comms exec departs; AI vet joins Absci board; new Zymeworks CEO — Chad Cohen will step down as CFO of Adaptive Biotechnologies on Feb. 15. Prior to joining Adaptive in 2015,… Read More
